Articles

Results 1 to 5 of 17


Is the Label Skinny Enough?

USA - April 19 2022 In this podcast, Finnegan attorneys Mark Feldstein, Cora Holt, and Tom Irving discuss the impacts of the recent Federal Circuit cases GSK v. Teva and…

Cora R. Holt, Thomas L. Irving

Federal Circuit Crystallizes BMS’ Apixaban District Court Win

USA - September 27 2021 In BMS v. Sigmapharm Labs. LLC., --F.3d __ (Fed. Cir. Sept. 3, 2021) the Federal Circuit affirmed the district court decision holding the asserted…

Thomas L. Irving, Stacy Lewis†, Jill K. MacAlpine, Ph.D., Paul W. Browning Ph.D., Melissa C. Santos, Ph.D.

“All Substantial Rights” and Right to Prosecute May Be Informative for Assessing Obviousness-Type Double Patenting Common Ownership but Was Not Found Where Assignee Retained Secondary Right of Enforcement

USA - July 8 2020 Holding: In Immunex Corp. v. Sandoz Inc., No. 2020-1037 (Fed. Cir. July 1, 2020) (O’MALLEY, Chen, Reyna) (Reyna, dissenting), the Federal Circuit…

Thomas L. Irving, Stacy Lewis

A Non-Precedential Case Study: Federal Circuit Says District Court Did Not Clearly Err in Holding Dosing Patent Invalid Based on Obviousness and Obviousness Type Double Patenting

USA - June 1 2020 Holding: In Boehringer Ingelheim Pharms. Inc. v. Mylan Pharms. Inc., No. 2019-1172 (Fed. Cir. March 16, 2020) (non-precedential), the Federal Circuit…

Adriana L. Burgy, Thomas L. Irving, Stacy Lewis, Jill K. MacAlpine, Ph.D.

Dissecting What the Prior Art Taught to Sustain Validity of Orange Book Patents Even Though Plaintiffs’s Reliance on Objective Evidence Came a Cropper

USA - May 1 2020 Holding: Judge Connolly in the District of Delaware decided in Cephalon, Inc. v. Slayback Pharma LLC, No. 1:17-cv-01154 (D. Del. April 27, 2020) that…

Justin J. Hasford, Thomas L. Irving, Stacy Lewis